{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T18:06:44Z","timestamp":1778350004995,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00392-020-01697-8","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T17:04:31Z","timestamp":1593709471000},"page":"183-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-6838","authenticated-orcid":false,"given":"Nuno","family":"Fernandes","sequence":"first","affiliation":[]},{"given":"Lu\u00edsa","family":"Prada","sequence":"additional","affiliation":[]},{"given":"M\u00e1rio Miguel","family":"Rosa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-5113","authenticated-orcid":false,"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-4921","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8034-4529","authenticated-orcid":false,"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-5673","authenticated-orcid":false,"given":"Daniel","family":"Caldeira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"issue":"1","key":"1697_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1525-1497.2005.00269.x","volume":"21","author":"BD Thombs","year":"2006","unstructured":"Thombs BD, Bass EB, Ford DE et al (2006) Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 21(1):30\u201338. https:\/\/doi.org\/10.1111\/j.1525-1497.2005.00269.x","journal-title":"J Gen Intern Med"},{"key":"1697_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2015.04.004","volume":"181","author":"H-J Kang","year":"2015","unstructured":"Kang H-J, Stewart R, Bae K-Y et al (2015) Predictors of depressive disorder following acute coronary syndrome: Results from K-DEPACS and EsDEPACS. J Affect Disord 181:1\u20138. https:\/\/doi.org\/10.1016\/j.jad.2015.04.004","journal-title":"J Affect Disord"},{"issue":"5","key":"1697_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ahj.2006.05.006","volume":"152","author":"AA Amin","year":"2006","unstructured":"Amin AA, Jones AMH, Nugent K, Rumsfeld JS, Spertus JA (2006) The prevalence of unrecognized depression in patients with acute coronary syndrome. Am Heart J 152(5):928\u2013934. https:\/\/doi.org\/10.1016\/j.ahj.2006.05.006","journal-title":"Am Heart J"},{"issue":"3","key":"1697_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.genhosppsych.2011.02.007","volume":"33","author":"A Meijer","year":"2011","unstructured":"Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P (2011) Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry 33(3):203\u2013216. https:\/\/doi.org\/10.1016\/j.genhosppsych.2011.02.007","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"1697_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/aje\/kwv227","volume":"183","author":"M Osler","year":"2016","unstructured":"Osler M, M\u00e5rtensson S, Wium-Andersen IK et al (2016) Depression after first hospital admission for acute coronary syndrome: a study of time of onset and impact on survival. Am J Epidemiol 183(3):218\u2013226. https:\/\/doi.org\/10.1093\/aje\/kwv227","journal-title":"Am J Epidemiol"},{"issue":"12","key":"1697_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1161\/CIR.0000000000000019","volume":"129","author":"JH Lichtman","year":"2014","unstructured":"Lichtman JH, Froelicher ES, Blumenthal JA et al (2014) Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 129(12):1350\u20131369. https:\/\/doi.org\/10.1161\/CIR.0000000000000019","journal-title":"Circulation"},{"key":"1697_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy913","author":"V Vaccarino","year":"2019","unstructured":"Vaccarino V, Badimon L, Bremner JD et al (2019) Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehy913","journal-title":"Eur Heart J."},{"issue":"11","key":"1697_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00392-019-01488-w","volume":"108","author":"C Albus","year":"2019","unstructured":"Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B, Kindermann I, K\u00f6llner V, Leith\u00e4user B, Marx N, Meesmann M, Michal M, Ronel J, Scherer M, Schrader V, Schwaab B, Weber CS, Herrmann-Lingen C (2019) Significance of psychosocial factors in cardiology: update 2018. Clin Res Cardiol 108(11):1175\u20131196","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"1697_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0002-9149(01)01675-7","volume":"88","author":"DE Bush","year":"2001","unstructured":"Bush DE, Ziegelstein RC, Tayback M et al (2001) Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 88(4):337\u2013341. https:\/\/doi.org\/10.1016\/S0002-9149(01)01675-7","journal-title":"Am J Cardiol"},{"issue":"1","key":"1697_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/archgenpsychiatry.2007.4","volume":"65","author":"N Frasure-Smith","year":"2008","unstructured":"Frasure-Smith N, Lesp\u00e9rance F (2008) Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry 65(1):62. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2007.4","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1697_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CRD.0b013e31820e8106","volume":"19","author":"CM Celano","year":"2011","unstructured":"Celano CM, Huffman JC (2011) Depression and cardiac disease. Cardiol Rev 19(3):130\u2013142. https:\/\/doi.org\/10.1097\/CRD.0b013e31820e8106","journal-title":"Cardiol Rev"},{"issue":"6","key":"1697_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/01.psy.0000146332.53619.b2","volume":"66","author":"J Barth","year":"2004","unstructured":"Barth J, Schumacher M, Herrmann-Lingen C (2004) Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 66(6):802\u2013813. https:\/\/doi.org\/10.1097\/01.psy.0000146332.53619.b2","journal-title":"Psychosom Med"},{"issue":"6","key":"1697_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/01.psy.0000146294.82810.9c","volume":"66","author":"JP van Melle","year":"2004","unstructured":"van Melle JP, de Jonge P, Spijkerman TA et al (2004) Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 66(6):814\u2013822. https:\/\/doi.org\/10.1097\/01.psy.0000146294.82810.9c","journal-title":"Psychosom Med"},{"issue":"4","key":"1697_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jama.2018.9422","volume":"320","author":"J-MJ-WH Kim","year":"2018","unstructured":"Kim J-MJ-WH, Stewart R, Lee Y-S et al (2018) Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome. JAMA 320(4):350. https:\/\/doi.org\/10.1001\/jama.2018.9422","journal-title":"JAMA"},{"issue":"9","key":"1697_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archgenpsychiatry.2009.121","volume":"66","author":"AH Glassman","year":"2009","unstructured":"Glassman AH, Bigger JT, Gaffney M (2009) Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Arch Gen Psychiatry 66(9):1022. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2009.121","journal-title":"Arch Gen Psychiatry"},{"issue":"18","key":"1697_CR16","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.116.025140","volume":"135","author":"KG Smolderen","year":"2017","unstructured":"Smolderen KG, Buchanan DM, Gosch K et al (2017) Depression treatment and 1-year mortality after acute myocardial infarction. Circulation 135(18):1681\u20131689. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025140","journal-title":"Circulation"},{"key":"1697_CR17","unstructured":"National Institute for Health and Clinical Excellence (2009) Depression: the treatment and management of depression in adults (update).\u00a0(Clinical guideline 90).\u00a0https:\/\/www.nice.org.uk\/guidance\/CG90. Accessed 21 May 2020"},{"issue":"17","key":"1697_CR18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.108.190769","volume":"118","author":"JH Lichtman","year":"2008","unstructured":"Lichtman JH, Bigger JT, Blumenthal JA et al (2008) Depression and coronary heart disease. Circulation 118(17):1768\u20131775. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.190769","journal-title":"Circulation"},{"issue":"1","key":"1697_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1370\/afm.918","volume":"7","author":"\u200bPost-Myocardial Infarction Depression Clinical Practice Guideline Panel","year":"2009","unstructured":"\u200bPost-Myocardial Infarction Depression Clinical Practice Guideline Panel\u00a0(2009) AAFP guideline for the detection and management of post-myocardial infarction depression. Ann Fam Med 7(1):71\u201379. https:\/\/doi.org\/10.1370\/afm.918","journal-title":"Ann Fam Med"},{"issue":"18","key":"1697_CR20","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1001\/jama.2008.667","volume":"300","author":"BD Thombs","year":"2008","unstructured":"Thombs BD, de Jonge P, Coyne JC et al (2008) Depression screening and patient outcomes in cardiovascular care. JAMA 300(18):2161. https:\/\/doi.org\/10.1001\/jama.2008.667","journal-title":"JAMA"},{"issue":"7","key":"1697_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.amjcard.2010.11.017","volume":"107","author":"C Pizzi","year":"2011","unstructured":"Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L (2011) Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 107(7):972\u2013979. https:\/\/doi.org\/10.1016\/j.amjcard.2010.11.017","journal-title":"Am J Cardiol"},{"key":"1697_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000238","author":"Y Kim","year":"2018","unstructured":"Kim Y, Lee YS, Kim MG et al (2018) The effect of selective serotonin reuptake inhibitors on major adverse cardiovascular events. Int Clin Psychopharmacol. https:\/\/doi.org\/10.1097\/YIC.0000000000000238","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"1697_CR23","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339(1):b2535\u2013b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"1697_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"1697_CR25","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v049.i05","author":"BC Wallace","year":"2012","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH (2012) Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. https:\/\/doi.org\/10.18637\/jss.v049.i05","journal-title":"J Stat Softw"},{"key":"1697_CR26","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A (eds) (2013) GRADE handbook for grading the quality of evidence and strength of recommendations. The GRADE Working Group. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed 21 May 2020"},{"key":"1697_CR27","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from\u00a0gradepro.org. Accessed 21 May 2020"},{"issue":"6","key":"1697_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/00006842-200011000-00007","volume":"62","author":"JJMH Strik","year":"2000","unstructured":"Strik JJMH, Honig A, Lousberg R et al (2000) Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 62(6):783\u2013789. https:\/\/doi.org\/10.1097\/00006842-200011000-00007","journal-title":"Psychosom Med"},{"issue":"4","key":"1697_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1067\/mhj.2001.116766","volume":"142","author":"A McFarlane","year":"2001","unstructured":"McFarlane A, Kamath MV, Fallen EL, Malcolm V, Cherian F, Norman G (2001) Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 142(4):617\u2013623. https:\/\/doi.org\/10.1067\/mhj.2001.116766","journal-title":"Am Heart J"},{"issue":"6","key":"1697_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jama.288.6.701","volume":"288","author":"AH Glassman","year":"2002","unstructured":"Glassman AH (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288(6):701. https:\/\/doi.org\/10.1001\/jama.288.6.701","journal-title":"JAMA"},{"key":"1697_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1745-0179-1-26","volume":"1","author":"PK Mohapatra","year":"2005","unstructured":"Mohapatra PK, Kar N, Kar GC, Behera M (2005) Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: six month prospective study on outcome. Clin Pract Epidemiol Ment Health 1:26. https:\/\/doi.org\/10.1186\/1745-0179-1-26","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"1697_CR32","unstructured":"Kennedy S (University of TOC) (2006) Synopsis-study 10413: a double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-000990-78\/results. Accessed 21 May 2020"},{"issue":"4","key":"1697_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jama.297.4.367","volume":"297","author":"F Lesp\u00e9rance","year":"2007","unstructured":"Lesp\u00e9rance F, Frasure-Smith N, Koszycki D et al (2007) Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease. JAMA 297(4):367. https:\/\/doi.org\/10.1001\/jama.297.4.367","journal-title":"JAMA"},{"issue":"01","key":"1697_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4088\/JCP.14m09281","volume":"76","author":"J-M Kim","year":"2015","unstructured":"Kim J-M, Bae K-Y, Stewart R et al (2015) Escitalopram treatment for depressive disorder following acute coronary syndrome. J Clin Psychiatry 76(01):62\u201368. https:\/\/doi.org\/10.4088\/JCP.14m09281","journal-title":"J Clin Psychiatry"},{"key":"1697_CR35","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2147\/NDT.S109880","volume":"12","author":"X Tian","year":"2016","unstructured":"Tian X, Wang Q, Guo R, Xu L, Chen QM, Hou Y (2016) Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatr Dis Treat 12:2333\u20132341. https:\/\/doi.org\/10.2147\/NDT.S109880","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"1697_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/YIC.0b013e32835d735d","volume":"28","author":"A Chittaranjan","year":"2013","unstructured":"Chittaranjan A, Chethan KB, Sandarsh S (2013) Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure. Int Clin Psychopharmacol 28(3):145\u2013155. https:\/\/doi.org\/10.1097\/YIC.0b013e32835d735d","journal-title":"Int Clin Psychopharmacol"},{"key":"1697_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijcme.2014.10.004","volume":"5","author":"C Pizzi","year":"2014","unstructured":"Pizzi C, Santarella L, Bugiardini R (2014) Epidemiology and the physiopathological link between depression and cardiovascular disease. IJC Metab Endocr 5:52\u201355. https:\/\/doi.org\/10.1016\/j.ijcme.2014.10.004","journal-title":"IJC Metab Endocr"},{"issue":"5","key":"1697_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000447034","volume":"85","author":"AF Carvalho","year":"2016","unstructured":"Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA (2016) The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 85(5):270\u2013288. https:\/\/doi.org\/10.1159\/000447034","journal-title":"Psychother Psychosom"},{"issue":"7","key":"1697_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/archpsyc.62.7.792","volume":"62","author":"CB Taylor","year":"2005","unstructured":"Taylor CB (2005) Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62(7):792. https:\/\/doi.org\/10.1001\/archpsyc.62.7.792","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1697_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00392-018-1208-4","volume":"107","author":"XY Fang","year":"2018","unstructured":"Fang XY, Spieler D, Albarqouni L, Ronel J, Ladwig KH (2018) Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study. Clin Res Cardiol 107(6):471\u2013478. https:\/\/doi.org\/10.1007\/s00392-018-1208-4","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"1697_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00392-019-01511-0","volume":"109","author":"A Peikert","year":"2020","unstructured":"Peikert A, Kaier K, Merz J, Manhart L, Sch\u00e4fer I, Hilgendorf I, Hehn P, Wolf D, Willecke F, Sheng X, Clemens A, Zehender M, von Zur MC, Bode C, Zirlik A, Stachon P (2020) Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort. Clin Res Cardiol 109(3):315\u2013323. https:\/\/doi.org\/10.1007\/s00392-019-01511-0","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01697-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-020-01697-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01697-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:03:13Z","timestamp":1625184193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-020-01697-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01697-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JJF had speaker and consultant fees with Gr\u00fcnenthal, Funda\u00e7\u00e3o MSD (Portugal), TEVA, MSD, Allergan, Medtronic, GlaxoSmithKline, Novartis, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion-Pharmaceuticals. FJP had consultant and speaker fees with Astra Zeneca, Bayer, BMS, Boehringer Ingelheim, and Daiichi Sankyo. DC has participated in educational meetings and\/or attended conferences or symposia (including travel, accommodation, and\/or hospitality) with Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck Serono, Ferrer, Pfizer, Novartis, and Roche. The remaining authors do not have interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}